⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107894 | 0.81 | — | — | |
| SCHEMBL71151 | 0.81 | — | — | |
| SCHEMBL1958871 | 0.74 | — | — | |
| SCHEMBL13419065 | 0.74 | — | — | |
| SCHEMBL3259977 | 0.72 | — | — | |
| SCHEMBL38661662 | 0.70 | — | — | |
| SCHEMBL2223384 | 0.70 | — | — | |
| SCHEMBL20516826 | 0.70 | — | — | |
| SCHEMBL15637388 | 0.70 | — | — | |
| SCHEMBL17437158 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230174544-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174544-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2021210911-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2021-10-21 | — | — | WO | disclosed |
| WO-2011084439-A1 | TETRAHYDROCARBOLINE DERIVATIVES AS EG5 INHIBITORS | SANOFI (FR) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084439-A1 | TETRAHYDROCARBOLINE DERIVATIVES AS EG5 INHIBITORS | SANOFI (FR) | 2011-07-14 | — | — | WO | disclosed |
| US-7563900-B2 | Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-07-21 | — | — | US | disclosed |